Login / Signup

Improvement of islet transplantation by the fusion of islet cells with functional blood vessels.

Lisa NalbachLeticia P RomaBeate M SchmittVivien BeckerChristina KörbelSelina WrublewskyMandy PackThomas SpäterWolfgang MetzgerMaximilian M MengerFlorian S FruehClaudia GötzHaopeng LinJoseline E Manning FoxPatrick E MacDonaldMichael D MengerMatthias W LaschkeEmmanuel Ampofo
Published in: EMBO molecular medicine (2020)
Pancreatic islet transplantation still represents a promising therapeutic strategy for curative treatment of type 1 diabetes mellitus. However, a limited number of organ donors and insufficient vascularization with islet engraftment failure restrict the successful transfer of this approach into clinical practice. To overcome these problems, we herein introduce a novel strategy for the generation of prevascularized islet organoids by the fusion of pancreatic islet cells with functional native microvessels. These insulin-secreting organoids exhibit a significantly higher angiogenic activity compared to freshly isolated islets, cultured islets, and non-prevascularized islet organoids. This is caused by paracrine signaling between the β-cells and the microvessels, mediated by insulin binding to its corresponding receptor on endothelial cells. In vivo, the prevascularized islet organoids are rapidly blood-perfused after transplantation by the interconnection of their autochthonous microvasculature with surrounding blood vessels. As a consequence, a lower number of islet grafts are required to restore normoglycemia in diabetic mice. Thus, prevascularized islet organoids may be used to improve the success rates of clinical islet transplantation.
Keyphrases
  • induced apoptosis
  • endothelial cells
  • type diabetes
  • cell cycle arrest
  • stem cells
  • cell therapy
  • cell proliferation
  • mesenchymal stem cells
  • adipose tissue
  • skeletal muscle
  • rectal cancer
  • replacement therapy